GeneDx is trading 4.8% down at $65.68 as the stock gives back gains from a recent rally amid broader biotech sector weakness.
- The decline follows a sharp 8.28% rebound on July 30, which had lifted the stock to $68.96.
- No company-specific news was reported, but the move aligns with a 3.15% drop in the SPDR S&P Biotech ETF (XBI) during a session marked by general risk-off sentiment.
- The stock is currently retracing a portion of its recent multi-day rally during mixed market conditions.